I Bernabeu1, A Pico2, E Venegas3, J Aller4, C Alvarez-Escolá5, J A García-Arnés6, M Marazuela7, P Jonsson8, N Mir9, M García Vargas9. 1. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain. 2. Hospital General Universitario de Alicante, Alicante, Spain. antonio.pico@goumh.umh.es. 3. Hospital Universitario Virgen del Rocío, Seville, Spain. 4. Hospital Universitario Puerta de Hierro - Majadahonda, Madrid, Spain. 5. Hospital Universitario La Paz, Madrid, Spain. 6. Hospital Regional Universitario de Málaga, Málaga, Spain. 7. Hospital Universitario de La Princesa, Madrid, Spain. 8. Pfizer Endocrine Care, Sollentuna, Sweden. 9. Pfizer Medical Department, Madrid, Spain.
Abstract
PURPOSE: To evaluate the long-term safety of Pegvisomant (PEG) in the Spanish cohort of ACROSTUDY. METHODS: As of July 2013, 199 Spanish patients were included in ACROSTUDY, a global non interventional safety PEG surveillance study. Patients were observed for safety, biochemical outcome and magnetic resonance imaging evaluations. RESULTS: PEG was administered during an average period of 6.7 ± 2.1 years and a mean daily dose of 15.5 ± 7.5 mg. 48.2% of patients received PEG monotherapy. 90.9% of patients had received other medical treatment before PEG start. 195 adverse events (AEs) were reported in 88 patients (44.2%), and serious AEs were described in 31 patients (15.6%). There were no cases of liver tests >10 ULN, or permanent liver damage. Tumor size changes were locally reported in 61 cases (33.5%), with increases observed in 11 patients (6%). In acromegalic patients with diabetes mellitus a decrease in fasting serum glucose value was reported, reaching statistical significance after 1 and 4 years of treatment (-24.6 and -25.9 mg/dl, p = 0.04). After 60 months, normal or lower limit of normal (LLN) IGF-I levels were found in 67.9% of patients. 85.5% of patients showed an IGF-I normal or <LLN at any time after PEG start. Most patients with uncontrolled IGF-I levels were on submaximal PEG doses. CONCLUSIONS: ACROSTUDY carried out with the Spanish cohort confirmed that PEG has a favorable safety and efficacy profile. The percentage of patients considered under control was similar to data reported globally and in other local ACROSTUDY results.
PURPOSE: To evaluate the long-term safety of Pegvisomant (PEG) in the Spanish cohort of ACROSTUDY. METHODS: As of July 2013, 199 Spanish patients were included in ACROSTUDY, a global non interventional safety PEG surveillance study. Patients were observed for safety, biochemical outcome and magnetic resonance imaging evaluations. RESULTS:PEG was administered during an average period of 6.7 ± 2.1 years and a mean daily dose of 15.5 ± 7.5 mg. 48.2% of patients received PEG monotherapy. 90.9% of patients had received other medical treatment before PEG start. 195 adverse events (AEs) were reported in 88 patients (44.2%), and serious AEs were described in 31 patients (15.6%). There were no cases of liver tests >10 ULN, or permanent liver damage. Tumor size changes were locally reported in 61 cases (33.5%), with increases observed in 11 patients (6%). In acromegalicpatients with diabetes mellitus a decrease in fasting serum glucose value was reported, reaching statistical significance after 1 and 4 years of treatment (-24.6 and -25.9 mg/dl, p = 0.04). After 60 months, normal or lower limit of normal (LLN) IGF-I levels were found in 67.9% of patients. 85.5% of patients showed an IGF-I normal or <LLN at any time after PEG start. Most patients with uncontrolled IGF-I levels were on submaximal PEG doses. CONCLUSIONS: ACROSTUDY carried out with the Spanish cohort confirmed that PEG has a favorable safety and efficacy profile. The percentage of patients considered under control was similar to data reported globally and in other local ACROSTUDY results.
Authors: A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner Journal: Lancet Date: 2001-11-24 Impact factor: 79.321
Authors: Michael Droste; Julia Domberg; Michael Buchfelder; Klaus Mann; Anja Schwanke; Günter Stalla; Christian J Strasburger Journal: Eur J Endocrinol Date: 2014-07 Impact factor: 6.664
Authors: M Ragonese; S Grottoli; P Maffei; A Alibrandi; M R Ambrosio; G Arnaldi; A Bianchi; S Puglisi; M C Zatelli; L De Marinis; E Ghigo; A Giustina; F Maffezzoni; C Martini; L Trementino; S Cannavo Journal: J Endocrinol Invest Date: 2017-10-28 Impact factor: 4.256
Authors: Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers Journal: Endocr Relat Cancer Date: 2017-07-21 Impact factor: 5.678
Authors: Laura Sánchez-Cenizo; Javier Aller; José Manuel Martínez-Sesmero; Nuria Mir; Carmen Peral; Darío Rubio-Rodríguez; Carlos Rubio-Terrés Journal: Clinicoecon Outcomes Res Date: 2019-07-22
Authors: Maria Fleseriu; Dagmar Führer-Sakel; Aart J van der Lely; Laura De Marinis; Thierry Brue; Joli van der Lans-Bussemaker; Judith Hey-Hadavi; Cecilia Camacho-Hubner; Michael P Wajnrajch; Srinivas Rao Valluri; Andrew Anthony Palladino; Roy Gomez; Roberto Salvatori Journal: Eur J Endocrinol Date: 2021-08-27 Impact factor: 6.664